clinical trial · NCT06545097
A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty
Tris Pharma, Inc.·phase3·completed·n = 279
Acute PainCebranopadol 400 ugCebranopadol 200 ugPlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.
started
Sep 3, 2024
primary completion
Dec 30, 2024
completion
Dec 30, 2024
last updated
Jan 22, 2026
detailed description
This study is a Phase 3, multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain after Full Abdominoplasty. This study will be conducted in 3 phases: Screening, Treatment, and Follow-up.
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain After Full Abdominoplasty
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol